What is the recommended dosing schedule for docetaxel 50 mg/m² on days 1 and 14 with prednisone 5 mg twice daily continuously, administered every two weeks?

Docetaxel 50 mg/m² Every 2 Weeks is NOT the Standard Regimen for Metastatic Prostate Cancer

The FDA-approved and guideline-recommended standard dose for docetaxel in metastatic castration-resistant prostate cancer is 75 mg/m² every 3 weeks with prednisone 5 mg twice daily continuously, NOT 50 mg/m² every 2 weeks. 1

Standard Dosing Regimen

The FDA label explicitly states for metastatic castration-resistant prostate cancer: docetaxel 75 mg/m² every 3 weeks as a 1-hour intravenous infusion with prednisone 5 mg orally twice daily administered continuously. 1

ASCO guidelines reinforce this, recommending six doses of docetaxel at 75 mg/m² administered at 3-week intervals for metastatic noncastrate prostate cancer with high-volume disease. 2 The NCCN guidelines similarly designate the 75 mg/m² every 3 weeks regimen as the category 1 standard. 3

When to Consider the 2-Weekly Regimen

The 50 mg/m² every 2 weeks schedule is NOT standard but may be considered as an alternative in specific clinical scenarios:

Patient Selection Criteria for 2-Weekly Dosing:

• Elderly patients (particularly ≥65 years)
• Poor performance status (ECOG ≥2)
• High comorbidity burden (elevated Charlson Comorbidity Index)
• Patients at high risk for febrile neutropenia where the standard regimen is unlikely to be tolerated
• Frail patients requiring palliation

3, 4, 5

Evidence Supporting 2-Weekly Dosing:

A randomized phase 3 trial (346 patients) showed that 50 mg/m² every 2 weeks resulted in:

• Improved time to treatment failure (5.6 vs 4.9 months, p=0.014)
• Significantly reduced febrile neutropenia (4% vs 14%)
• Fewer neutropenic infections (6% vs 24%, p=0.002)
• Lower grade 3-4 neutropenia (36% vs 53%)

However, overall survival was numerically but not statistically superior (19.5 vs 17.0 months, p=0.015). 4

Critical Caveats

The 2-weekly regimen has NOT been validated in the landmark trials (TAX 327, CHAARTED, STAMPEDE) that established docetaxel's survival benefit in prostate cancer. 2, 3 Real-world data suggests patients receiving 2-weekly dosing tend to be older, frailer, and have worse baseline characteristics, which may confound outcomes. 5

The NCCN explicitly states it does NOT currently recommend alternative dosing schedules as standard, noting that the biweekly regimen is based on a single phase 2 trial in the mCRPC setting. 3

Premedication Requirements

Regardless of schedule, premedication with dexamethasone is mandatory:

• For metastatic castration-resistant prostate cancer (given concurrent prednisone use): dexamethasone 8 mg at 12 hours, 3 hours, and 1 hour before docetaxel infusion 1

Algorithmic Approach

For fit patients with metastatic prostate cancer:

• Use 75 mg/m² every 3 weeks (standard, category 1) 2, 3, 1

For elderly/frail patients (ECOG ≥2, high comorbidity, high neutropenia risk):

• Consider 50 mg/m² every 2 weeks as an alternative 3, 4, 5
• Recognize this is off-label and lacks robust survival data
• Monitor closely for cumulative toxicities (nail changes, lacrimation) that may worsen with more frequent dosing 6

Bottom line: The regimen you've described (50 mg/m² on days 1 and 14 every 2 weeks) is a recognized alternative for selected patients but is NOT the standard of care. Default to 75 mg/m² every 3 weeks unless patient-specific factors mandate dose reduction.